Evidence map›Paper›PMID 38735482›Full record

ArticleJournal of substance use and addiction treatment2024

Perspectives on benefits and risks of creation of an "injection drug use" billing code.

Gayathri Sundaram, Taisuke Sato, David Goodman-Meza, Marwan Haddad, Kinna Thakarar, Judith Feinberg, Sandra A Springer, Kerri Barton, Nikki Butler, Ellen F Eaton and 1 more

Abstract readEditorial
In one paragraph

Article in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gayathri SundaramTufts University School of Medicine, Boston, MA, United States of America.
Taisuke SatoTufts Medical Center, Boston, MA, United States of America.
David Goodman-MezaDavid Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.
Marwan HaddadCenter for Key Populations, Community Health Center, Inc., Middletown, CT, United States of America.
Kinna ThakararTufts University School of Medicine, Boston, MA, United States of America; Maine Health Institute of Research, Portland, ME, United States of America; Maine Medical Center, Portland, ME, United States of America; Maine Medical Partners Adult Infectious Diseases, South Portland, ME, United States of America; West Virginia University School of Medicine, Morgantown, WV, United States of America.
Judith FeinbergWest Virginia University School of Medicine, Morgantown, WV, United States of America.
Sandra A SpringerYale University School of Medicine, New Haven, CT, United States of America; Yale University School of Public Health, New Haven, CT, United States of America.
Kerri BartonHarm Reduction Program Coordinator, Portland Public Health, Portland, ME, United States of America.
Nikki ButlerMaine Access Points, Portland, ME, United States of America.
Ellen F EatonUniversity of Alabama at Birmingham, Birmingham, AL, United States of America.
Alysse G WurcelTufts University School of Medicine, Boston, MA, United States of America; Tufts Medical Center, Boston, MA, United States of America. Electronic address: Alysse.Wurcel@tuftsmedicine.org.

Funding

Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They LiveDP1DA056106 · NIDA · YALE UNIVERSITY · PI SANDRA Ann SPRINGER · 2022 to 2026
$6.0M
Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infectionsK08DA048163 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOODMAN, DAVID · 2019 to 2023
$1.0M
NIDA NIH HHS DP1 DA056106NIDA NIH HHS K08 DA048163
6 · The paper itself

Abstract

People with substance use disorder (SUD) face barriers to prevention and treatment services, increasing risk for hospitalization and death. Injection drug use (IDU) can lead to an increased risk of overdose and infections. However, identifying people who inject drugs (PWID) within healthcare systems is challenging. International Classification of Disease (ICD-10) codes are used for billing and tracking healthcare utilization. In this commentary, experts in the field weigh the benefits and risks of creating an IDU-specific ICD-10 code. Potential benefits include earlier identification, better access to health services, and improved systems of resource allocation. Potential risks include further stigmatization of PWID and, if not tied to financial reimbursement, low rates of code utilization. As the current systems of identifying PWID are lacking, we feel that a guided operationalization of an ICD code to identify PWID could improve quantitative and epidemiological research accuracy and, therefore, support the health and well-being of PWID.

Indexed as

International Classification of DiseasesSubstance Abuse, IntravenousHealth Services AccessibilityHumansRisk Assessment

Identifiers

PMID38735482
PMCPMC13112322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.